Inflammation  >>  elbasvir (MK-8742)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elbasvir (MK-8742) / Merck (MSD)
MK-3682-011, NCT02332707 / 2014-003304-73: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection

Completed
2
443
NA
Grazoprevir, MK-5172, Uprifosbuvir, MK-3682, Elbasvir, MK-8742, Ruzasvir, MK-8408, Uprifosbuvir (+) Grazoprevir (+) Ruzasvir, MK-3682B, Ribavirin, Rebetol®
Merck Sharp & Dohme LLC
Hepatitis C
09/16
12/16
NCT02332720 / 2014-003347-35: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

Completed
2
413
NA
Grazoprevir, MK-5172, Uprifosbuvir, MK-3682, Elbasvir, MK-8742, Ruzasvir, MK-8408, MK-3682B, Ribavirin (RBV), Rebetol
Merck Sharp & Dohme LLC
Hepatitis C
09/16
05/17

Download Options